A comprehensive resource for heart and vascular services.

  • Increase/Decrease Text Size
  • Print This Page
Back to Results Back to Search

Ronald D. Alvarez, M.D.


Professor and Director, Divison of Gynecologic Oncology


  • Specialty
  • Sub - Specialty
    • Gynecologic Cancer - Robotic Surgery
    • Robotic Surgery
    • Gynecologic Cancer
  • Phone
    • (205) 934-9999
    • 1-800-UAB-8816
  • Primary Clinic Location
  • Hospital Affiliation

    UAB Hospital

    Baptist Health Montgomery

    UAB Highlands

  • Print this profile


Education and Training
  • Medical School
    • LSU Medical School
    • 1983
  • Internship
    • University of Alabama at Birmingham
    • 1983 - 1984
  • Residency
    • University of Alabama at Birmingham
    • 1984 - 1987
  • Fellowship
    • University of Alabama at Birmingham
    • 1987 - 1990
  • American Board of Gynecologic Oncology 1992
  • American Board of OB/GYN 1991
  • American Board of Gynecologic Oncology Recertification 2002
  • American Board of OB/GYN Recertification 2002

Clinic Information

Locations and Directions
Women & Infants Center
1700 6th Ave South
Birmingham, AL 35233

Clinical Interests

Clinical Interests
  • GYN cancers
  • Chemo/infusion therapy
  • Robotic surgery for endometrial cancer
  • Cervical cancer prevention




1. Matthews KS, Curiel DT, Alvarez RD. Advancements in oncolytic therapies for ovarian cancer. Adv Drug Deliv Rev. 61(10): 836-841, 2009.

2. Alvarez RD, Mannel R, Garcia AA, Gallion HH, Lucci J 3rd, Kilgore LC, Numnum TM, Zou SX, Orlando M, Tai DF. Fixed-dose rate gemcitabine plus carboplatin in relapsed, platinum-sensitive ovarian cancer patients: results of a three-arm Phase I study. Gynecol Oncol. 115(3):389-95, 2009.

3. Anwer, K, Barnes MN, Fewell J, Lewis DH, Alvarez RD. Phase-I clinical trial of IL-12 plasmid/lipopolymer complexes for the treatment of ovarian cancer. Gene Ther. 17(3):360-9, 2010.

4. Kimball KJ, Preuss MA, Barnes MN, Wang M, Siegal GP, Wan W, Kuo H, Saddekni S, Stockard CR, Grizzle WE, Harris RD, Aurigemma R, Curiel DT, Alvarez RD. A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases. Clin Cancer Res. 1;16(21):5277-87, 2010.

5. Whitworth JM, Alvarez RD. Evaluationg the role of IL-12 based therapies in ovarian cancer: A review of the literature. Expert Opinion on Biological Therapy Expert Opin Biol Ther 11(6):751-62, 2011

6. Kim KH, Ryan MJ, Estep JE, Miniard BM, Rudge TL, Peggins JO, Broadt TL, Wang M, Preuss MA, Siegal GP, Hemminki A, Harris RD, Aurigemma R, Curiel DT, Alvarez RD.
A new generation of serotype chimeric infectivity-enhanced conditionally replicative adenovirals: The safety profile of Ad5/3-Δ24 in advance of a phase I clinical trial in ovarian cancer patients. Hum Gene Ther. 22(7):821-8, 2011.

7. Steg AD, Bevis KS, Katre AA, Ziebarth A, Alvarez RD, Zhang K, Conner MB, Landen CN Jr. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res. 18:869-81, 2011.

8. Ziebarth AJ, Landen CN, Alvarez RD. Molecular/Genetic Therapies in Ovarian Cancer – Future Opportunities and Challenges. Clinical Obstetrics and Gynecology 55:156-72, 2012.

9. Kim KH, Dmitriev I, O'Malley JP, Wang M, Saddekni S, You Z, Preuss MA, Harris RD, Aurigemma R, Siegal GP,Zinn KR, Curiel DT, Alvarez RD. A phase I clinical trial of Ad5.SSTR/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer. Clin Cancer Res 18(12):3440-51, 2012.


Research Interests
  • Gene therapy
  • Other novel therapeutics for ovarian cancer
  • Novel cervical cancer vaccines

Attention UAB Physicians

If you are a physician on the UAB medical staff and would like to modify your profile, please e-mail your changes to the program administrator

Update Profile